PRV131
Intratumoral Injectable for Oral Cavity Cancer
Phase 1/2Active
Key Facts
Indication
Intratumoral Injectable for Oral Cavity Cancer
Phase
Phase 1/2
Status
Active
Company
About Privo Technologies
Privo Technologies is a private, pre-revenue biotech founded in 2019 and based in Cambridge, MA. The company's core asset is the PRV™ platform, a nanotechnology-enabled system for the localized delivery of chemotherapeutics (e.g., cisplatin) via patches, hydrogels, and injectables. Its pipeline is advanced, with PRV111 for oral carcinoma in situ in Phase 3, PRV211 for intraoperative use in Phase 1/2, and PRV131 as an intratumoral injectable in early clinical studies, all supported by over $20M in non-dilutive funding from U.S. government agencies.
View full company profile